about
Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutationsChemical genetic screen identifies lithocholic acid as an anti-aging compound that extends yeast chronological life span in a TOR-independent manner, by modulating housekeeping longevity assurance processesLithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cellsThe role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic controlBile acid transportersBile acids: regulation of synthesisMetabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseasesRecent advances in understanding and managing cholestasisHepatocellular carcinoma: Review of disease and tumor biomarkersPathophysiological role of host microbiota in the development of obesityTreatment of nonalcoholic steatohepatitis in adults: present and futureBile acid metabolism and signalingThe Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know.Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?Bile acids, obesity, and the metabolic syndromeBridging cell surface receptor with nuclear receptors in control of bile acid homeostasisBile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytesBile acid nuclear receptor FXR and digestive system diseasesRole of farnesoid X receptor and bile acids in alcoholic liver diseaseFXR is a molecular target for the effects of vertical sleeve gastrectomyBile acid signaling in metabolic disease and drug therapyConjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expressionStructure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acidsSteroid binding to Autotaxin links bile salts and lysophosphatidic acid signallingFarnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivoRole of the intestinal bile acid transporters in bile acid and drug dispositionLithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activationNovel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in MiceDiet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levelsCystic fibrosis related liver disease--another black box in hepatology.FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathwaysEmpirical Validation of a Hypothesis of the Hormetic Selective Forces Driving the Evolution of Longevity Regulation MechanismsStructural and functional characterization of BaiA, an enzyme involved in secondary bile acid synthesis in human gut microbe.A quantitative metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis CCombined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis.GSAASeqSP: a toolset for gene set association analysis of RNA-Seq dataMetabolomics Coupled with Multivariate Data and Pathway Analysis on Potential Biomarkers in Cholestasis and Intervention Effect of Paeonia lactiflora Pall.The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.Commensal bacteria at the interface of host metabolism and the immune system.In vivo performance of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile acid transport
P2860
Q24301033-11451E7D-31D5-44E0-8512-39E4C2B31D95Q24616983-2409AE13-B4EB-4022-83EF-E3693DA62FCFQ24617423-D3C8D1FF-6CFC-49C7-A1C8-B576D38365F2Q24629879-F3C5F7A4-8FBC-4EAE-B9FE-122BA5D86546Q24652624-001D89DB-3744-477F-A51B-7D9716D8F603Q24658139-BCDF8BCE-4651-46E2-868A-262AF3D95E23Q26741550-4CE00E95-7648-47BF-86FD-EB92B404BFBCQ26748537-AE6637E3-1B9F-45E2-8487-A69A97E0B633Q26750796-EE74D128-67AD-41A2-A975-2E9ED5F5C641Q26750893-BC6B2338-6E99-4493-AB4B-84BADFD8372FQ26852403-1EE85E3A-024F-48C0-85DE-044361210430Q27002873-F339063B-4C15-4E2F-995E-6452146FC33EQ27008277-650D0332-F84C-49D9-91A6-AF97810A5774Q27015789-CBD88C1C-6928-4F25-9E9A-6CAAC39C6228Q27020976-33DCE5D4-8C26-4E50-8F78-A5EDD5A055B1Q27024221-698E4FF2-55C0-49DF-BA02-2114FE0F0445Q27332942-A982611D-2D3E-45F2-8977-902A03974A1CQ28085493-567A0137-A8B6-4A15-84F6-610234F582F1Q28086898-185225F9-3906-4D9B-BC18-E54709C2E904Q28236848-9724AA68-892D-4AC2-9794-135B77C3B773Q28244875-F1A4FC06-ECFB-4743-A219-7E18397584DFQ28250778-D5E2584D-BABE-4BA3-B3F3-A26DA78AA11BQ28257042-472667E7-7381-490F-B611-E7AB7F649E8BQ28274830-44903695-1211-4C19-AC4A-B53D9A74303BQ28296042-DE9712FA-C845-462A-949A-25C76DD363B6Q28299162-E913CD75-5212-4550-88EC-37B2474430DDQ28477562-72F01B11-B3C4-43BF-948B-9FE9E556DE57Q28547520-416C55AB-F080-46FD-A2CA-D14734DDB33CQ28593904-C387DEB8-7A44-4F47-8109-2CF4F36B402AQ28655881-22FED570-54EE-4C71-A910-C8CFD862F435Q28741802-FF498102-6E80-4B5F-BC61-D69B17E521AFQ28817899-5E155469-DFA5-44FF-813A-6C6AC75A6308Q30351948-4F7F272C-E2D4-426B-8349-8D43783E946FQ30375134-C69D304C-2FDC-448E-ABC0-451E1F73D873Q30433566-19B272A7-C0D2-4A87-9E84-873767D03DD9Q30850769-F61CB523-4F96-45EA-94CF-64BA94AC0A4AQ31044588-4411AAB6-72F1-456E-9418-63636CFD0DAEQ33570124-0388250E-21DB-4B39-A8E5-9C5E8D116C75Q33578547-9EAD7990-1651-48BB-AE5E-0E4C5BD182EDQ33598772-C6244243-1A4A-4F21-823D-D84FEFF0FD19
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting bile-acid signalling for metabolic diseases.
@en
Targeting bile-acid signalling for metabolic diseases.
@nl
type
label
Targeting bile-acid signalling for metabolic diseases.
@en
Targeting bile-acid signalling for metabolic diseases.
@nl
prefLabel
Targeting bile-acid signalling for metabolic diseases.
@en
Targeting bile-acid signalling for metabolic diseases.
@nl
P2093
P356
P1476
Targeting bile-acid signalling for metabolic diseases.
@en
P2093
Charles Thomas
Mark Pruzanski
Roberto Pellicciari
P2888
P304
P356
10.1038/NRD2619
P577
2008-08-01T00:00:00Z
P6179
1010308238